SCHEMBL6566774

SCHEMBL6566774

CC(C)N(CCCl)CCCl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
MAPT P10636 1/20 0.42
TSHR P16473 4/20 0.40
LMNA P02545 3/20 0.40
TP53 P04637 1/20 0.40
HTT P42858 1/20 0.40
HBB P68871 1/20 0.40
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
SLC22A2 O15244 1/20 0.32
SLC22A1 O15245 1/20 0.32
SLC22A3 O75751 1/20 0.32
ESR1 P03372 1/20 0.32
CHRM2 P08172 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
CHRM1 P11229 1/20 0.32
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6756617 0.97 MEN1 (0.55) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL14355539 0.89 MEN1 (0.48) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL12860961 0.85
Hydrochloric Acid SCHEMBL10746384 0.83 MEN1 (0.48) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL9004138 0.79 MEN1 (0.44) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL2990827 0.73 MEN1 (1.00) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL226273 0.73 MEN1 (1.00) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL1252790 0.73 MEN1 (0.43) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL5908848 0.71 MEN1 (0.42) MEN1KMT2AMAPTTSHRLMNA
SCHEMBL10716586 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692074-A1 CRBN LIGAND, PREPARATION METHOD THEREFOR, AND APPLICATION Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2026-02-11 EP claimed
EP-4644384-A1 CYP11A1 INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Lichun Biotech Co., Ltd. (CN) 2025-11-05 EP claimed
CN-113563245-B Substituted pyrrolidines and their use in medicine 广东东阳光药业股份有限公司 2024-10-15 CN claimed
WO-2024208331-A1 CRBN LIGAND, PREPARATION METHOD THEREFOR, AND APPLICATION 深圳众格生物科技有限公司 2024-10-10 WO claimed
WO-2024146383-A1 CYP11A1 INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海闻耐医药科技有限公司 2024-07-11 WO claimed
CN-118307519-A CYP11A1 inhibitor compound, preparation method and application thereof 上海闻耐医药科技有限公司 2024-07-09 CN claimed
CN-112390904-B Polyethylene containing polar functional groups and preparation method thereof 中国科学院上海有机化学研究所 2023-05-09 CN claimed
US-11447470-B2 Pyrimidinone-containing compound, preparation method thereof, pharmaceutical composition and application thereof YUNNAN UNIVERSITY (CN) 2022-09-20 US claimed
CN-114667290-A Yttrium or lanthanide metal precursor compounds, film-forming compositions containing the same, and methods of forming yttrium or lanthanide metal-containing films using the same UP化学株式会社 2022-06-24 CN claimed
WO-2022022364-A1 PYRROLIDINE INTEGRIN MODULATOR AND USE THEREOF 清药同创(北京)药物研发中心有限公司 2022-02-03 WO claimed
EP-4692074-A1 CRBN LIGAND, PREPARATION METHOD THEREFOR, AND APPLICATION Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2026-02-11 EP disclosed
EP-4644384-A1 CYP11A1 INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Lichun Biotech Co., Ltd. (CN) 2025-11-05 EP disclosed
WO-2025215579-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2025-10-16 WO disclosed
US-12378265-B2 Process for preparing organotin compounds ENTEGRIS, INC. (US) 2025-08-05 US disclosed
CN-113563245-B Substituted pyrrolidines and their use in medicine 广东东阳光药业股份有限公司 2024-10-15 CN disclosed
US-6197791-B1 ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY 2001-03-06 US disclosed
US-6172057-B1 ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY 2001-01-09 US disclosed
EP-0970046-A1 N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-01-12 EP disclosed
WO-1998038163-A1 N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1998-09-03 WO disclosed
US-5051363-A Decreasing the toxicity of nitrogen mustard gas UNIVERSITY OF PENNSYLVANIA (US) 1991-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11447470-B2 Pyrimidinone-containing compound, preparation method thereof, pharmaceutical composition and application thereof TYMP, DPYD, DHPS MEN1 2250/4885KMT2A 3182/4885MAPT 2435/4885
US-12378265-B2 Process for preparing organotin compounds ETV6, TPMT, TTN MEN1 296/4885KMT2A 346/4885MAPT 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.